Cargando…
Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma
Originally described as interpatient variability, tumour heterogeneity has now been demonstrated to occur intrapatiently, within the same lesion, or in different lesions of the same patient. Tumour heterogeneity involves both genetic and epigenetic changes. Intrapatient heterogeneity is responsible...
Autores principales: | Fattore, Luigi, Ruggiero, Ciro Francesco, Liguoro, Domenico, Mancini, Rita, Ciliberto, Gennaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823362/ https://www.ncbi.nlm.nih.gov/pubmed/31672982 http://dx.doi.org/10.1038/s41419-019-2048-5 |
Ejemplares similares
-
The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021) -
In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2020) -
ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin
por: Ruggiero, Ciro Francesco, et al.
Publicado: (2019) -
MicroRNAs in melanoma development and resistance to target therapy
por: Fattore, Luigi, et al.
Publicado: (2017) -
Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma
por: Fattore, Luigi, et al.
Publicado: (2020)